UBS analyst Colin Bristow upgraded Pfizer (PFE – Research Report) to Buy today and set a price target of $60.00. The company’s shares closed last Friday at $52.78, close to its 52-week high of $55.70.
According to TipRanks.com, Bristow is ranked 0 out of 5 stars with an average return of -10.0% and a 40.6% success rate. Bristow covers the Healthcare sector, focusing on stocks such as Bristol Myers, Biogen, and Omeros.
Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $53.69, which is a 4.9% upside from current levels. In a report issued on December 8, Wells Fargo also initiated coverage with a Buy rating on the stock with a $60.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Pfizer’s market cap is currently $296.2B and has a P/E ratio of 15.10. The company has a Price to Book ratio of -2848.53.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PFE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
